PKD1 and autosomal dominant polycystic kidney disease: A glycolysis antagonist exhibited potential in the treatment of ADPKD, whereas 2-deoxy-d-glucose (2DG), a glycolysis inhibitor, demonstrated some success in regulating cystogenesis in quickly growing Ksp-Cre, Pkd1flox, and Pkd1 V/V mice models of polycystic kidney disease.